These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15111692)

  • 1. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.
    Sormani MP; Rovaris M; Valsasina P; Wolinsky JS; Comi G; Filippi M
    Neurology; 2004 Apr; 62(8):1432-4. PubMed ID: 15111692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?
    Rovaris M; Comi G; Filippi M
    J Neurol Sci; 2005 Jun; 233(1-2):139-43. PubMed ID: 15949501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND
    Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract]   [Full Text] [Related]  

  • 6. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Filippi M; Rovaris M; Rocca MA; Sormani MP; Wolinsky JS; Comi G;
    Neurology; 2001 Aug; 57(4):731-3. PubMed ID: 11524494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
    Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M;
    Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis.
    Fritz DA; Dwyer MG; Bagnato F; Watts KL; Bratina A; Zorzon M; Durastanti V; Locatelli L; Millefiorini E; Zivadinov R
    Neurol Res; 2006 Apr; 28(3):275-9. PubMed ID: 16687053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences.
    Horsfield MA; Rovaris M; Rocca MA; Rossi P; Benedict RH; Filippi M; Bakshi R
    J Neurol Sci; 2003 Dec; 216(1):169-77. PubMed ID: 14607319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.
    Uher T; Krasensky J; Vaneckova M; Sobisek L; Seidl Z; Havrdova E; Bergsland N; Dwyer MG; Horakova D; Zivadinov R
    J Neuroimaging; 2017 Nov; 27(6):620-629. PubMed ID: 28464417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of inflammation on brain volume in multiple sclerosis.
    Cheriyan J; Kim S; Wolansky LJ; Cook SD; Cadavid D
    Arch Neurol; 2012 Jan; 69(1):82-8. PubMed ID: 22232347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis.
    Nakamura K; Guizard N; Fonov VS; Narayanan S; Collins DL; Arnold DL
    Neuroimage Clin; 2014; 4():10-7. PubMed ID: 24266007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.
    Storelli L; Rocca MA; Pagani E; Van Hecke W; Horsfield MA; De Stefano N; Rovira A; Sastre-Garriga J; Palace J; Sima D; Smeets D; Filippi M;
    Radiology; 2018 Aug; 288(2):554-564. PubMed ID: 29714673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.
    Jasperse B; Valsasina P; Neacsu V; Knol DL; De Stefano N; Enzinger C; Smith SM; Ropele S; Korteweg T; Giorgio A; Anderson V; Polman CH; Filippi M; Miller DH; Rovaris M; Barkhof F; Vrenken H;
    J Magn Reson Imaging; 2007 Oct; 26(4):881-5. PubMed ID: 17896359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.
    Ruberte E; Sinnecker T; Amann M; Gaetano L; Naegelin Y; Penner IK; Kuhle J; Derfuss T; Kappos L; Granziera C; Wuerfel J; Yaldizli Ö
    Eur Neurol; 2018; 80(3-4):207-214. PubMed ID: 30605898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.